OWKIN — NJF Capital Blog

Owkin appoints Alban de La Sablière as Chief Business Officer

AI biotech company Owkin has appointed Alban de La Sablière, formerly SVP Global Head of Partnering at Sanofi, as Chief Business Officer

OWKINJames StephensOctober 27, 2022

Green Light for Cancer Drugs Developed by AI Specialist Owkin

Owkin announced that two first-in-class rapid, affordable AI-based diagnostic solutions – designed to improve outcomes for patients with breast cancer and colorectal cancer – approved for use in Europe

OWKINJames StephensSeptember 2, 2022

This Unicorn is Betting on AI to Boost Drug Discovery. It’s Now a Step Closer

An EU-funded project has shown its potential to transform the pharma industry, according to Owkin

OWKINJames StephensJuly 20, 2022

Owkin Bags $180m BMS Alliance for Cardiovascular Clinical Trials

Bristol-Myers Squibb is paying $80 million upfront to tap into Owkin's expertise

OWKINJames StephensJune 9, 2022

Drugmaker Sanofi Invests $180m in French AI Startup Owkin

The deal gives Sanofi a stake between 10 and 15% in Owkin and turns the company into a "unicorn"

OWKINJames StephensNovember 18, 2021

AI Can Predict Risk of Recurrence for Women with Common Breast Cancer

Study from Gustave Roussy and Owkin shows that deep learning analysis in digitized pathology slides can help classify patients

OWKINJames StephensOctober 15, 2021

French-American AI Startup Owkin Closes $18 million Series A to Make Medical Research More Collaborative

Other investors in the Series A round, which was initially announced in 2018, include NJF Capital

OWKINJames StephensJune 30, 2020

COVID-19 Open AI Consortium – Interview with Owkin’s Sanjay Budhdeo, MD, Business Development

Owkin’s Covid-19 Open AI Consortium (COAI) intends to bring breakthrough medical discoveries and actionable findings to the fight against the Covid-19 pandemic.

OWKINJames StephensMay 13, 2020

Owkin Raises $25m as it Builds a Secure Network for Healthcare Analysis and Research

New investors in Owkin include Bpifrance Large Venture, Cathay Innovation and MACSF (the French Pension Fund for Clinicians), alongside existing investors including NJF Capital

OWKINJames StephensMay 8, 2020

Collaboration Established to Deliver Federated Learning in Life Sciences

Owkin has announced a collaboration with technology company NVIDIA and King’s College London

OWKINJames StephensDecember 5, 2019

Owkin's Mesothelioma AI Discovers New Biomarkers From Lung Biopsy Images

Owkin is working with biopharma partners to apply its artificial intelligence in patient selection for clinical trials by helping identify those most at risk.

OWKINJames StephensOctober 7, 2019